Cagrilintide
Late-stage pharmaceutical obesity program
Brief Overview: Cagrilintide is an amylin analog. In the CagriSema combination, it is paired with semaglutide so that one component strengthens satiety/satiation signaling while the GLP-1 component reduces appetite and improves glycemic control. Evidence lens: This one has substantially stronger evidence than most research peptides because it is supported by large Phase 3 obesity trials. The main beginner distinction is that CagriSema is not “stronger semaglutide”; It is a two-pathway fixed-dose product with its own tolerability and titration profile. How to read this: Once you're past the basics, compare CagriSema with tirzepatide and retatrutide using trial population, estimand, adherence, dose escalation, and adverse-event discontinuation, not just headline percent weight loss.
- Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk.
- In CagriSema, cagrilintide is paired with semaglutide as an investigational fixed-dose obesity product.
- Cagrilintide is a long-acting amylin analog, not a GLP-1 agonist. This distinction matters because it complements incretin drugs through satiety/amylin biology rather than duplicating GLP-1 signaling.
- Cagrilintide targets amylin and calcitonin-receptor pathways involved in satiety, meal termination, gastric emptying, and glucagon regulation.
- These pathways complement GLP-1 signaling rather than replacing it.
- The combination is intended to increase both appetite suppression and earlier meal satisfaction.
- The practical mechanism is appetite and weight regulation through amylin-receptor pathways, especially satiety and meal-size effects. It is not a glucose-control drug in the same way as GLP-1/GIP agonists. The mechanism here is a plausibility map, not proof of a clinical outcome.
- REDEFINE 1 reported 22.7% mean weight loss with full adherence for CagriSema 2.4 mg / 2.4 mg over 68 weeks.
- In the same dataset, the full-adherence monotherapy arms were semaglutide 2.4 mg at 16.1%, cagrilintide 2.4 mg at 11.8%, and placebo at 2.3%.
- Approximately 50.7% of participants with baseline obesity crossed below BMI 30 kg/m2 by the end of treatment.
- REDEFINE 2 evaluated adults with type 2 diabetes and overweight or obesity.
- REDEFINE 4 compared CagriSema with tirzepatide 15 mg and did not demonstrate noninferiority on the primary endpoint.
- Human evidence is mainly in obesity/metabolic clinical-trial contexts and especially combination development with semaglutide. The evidence base is stronger than most research peptides but still product- and indication-specific. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.
- Protocol 1: Clinical Titration (CagriSema) [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: Clinical/investigational titration: 0.25 mg weekly → 0.50 mg weekly → 1.0 mg weekly → 1.7 mg weekly; Month 5+ target depends on trial/product context.; Frequency: Once weekly; Max: CagriSema trial/product target: 2.4 mg cagrilintide + 2.4 mg semaglutide weekly; Cagrilintide monotherapy investigational rows may cite up to 4.5 mg.; Titration/loading: Month 1: 0.25 mg weekly; Month 2: 0.50 mg weekly; Month 3: 1.0 mg weekly; Month 4: 1.7 mg weekly; Month 5+: context-specific target.; Status: No - investigational; Not FDA-approved as of the April 2026 guide/current audit context.
- Protocol 2: CagriSema investigational maintenance target [Research/Experimental]; Route: Subcutaneous (SC); Dose: 2.4 mg cagrilintide weekly when used in fixed-dose/coadministered CagriSema with semaglutide 2.4 mg weekly; Frequency: Once weekly; Duration: Maintenance; Status: No - investigational; Not FDA-approved as of the April 2026 guide/current audit context.
- Dosing turns on trial protocol, combination product context, and titration. Do not import semaglutide or tirzepatide schedules into cagrilintide unless the studied combination is named. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
Cagrilintide is designed for once-weekly exposure. Practical pharmacokinetics depend on the final approved formulation and label.
- Time until steady state: about 4-6 weeks.
- Half-life basis: Cagrilintide 159-195 hours; Semaglutide component about 145-165 hours. This is why weekly titration and dose-escalation intervals matter; The final label controls once approved.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- Long-acting design supports weekly-style research and development protocols. Delayed GI effects and appetite changes can outlast perceived peak effects, so dose escalation matters. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- CagriSema is already a fixed-dose combination.
- Additional incretin, amylin, or appetite-suppressing drugs may increase adverse effects and are not an evidence-based stack.
- The most important stack is with GLP-1 therapy, especially CagriSema-style combinations. Stacking with other appetite suppressants or dehydration-prone regimens can compound nausea, low intake, and gallbladder risk. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Expected concerns include nausea, vomiting, constipation, delayed gastric emptying, dehydration risk, hypoglycemia risk when combined with insulin or sulfonylureas, pancreatitis warning context, and thyroid/C-cell contraindication language once final labeling is available.
- Expected issues include nausea, vomiting, reduced intake, possible hypoglycemia when combined with glucose-lowering drugs, and pancreatobiliary monitoring by class context. Avoid treating it as a harmless add-on to GLP-1 therapy. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Weight, waist circumference, hydration, HbA1c, glucose, renal function during dehydration risk, and GI tolerability are the most relevant monitoring categories.
- Track weight rate, appetite, GI tolerance, hydration, glucose if diabetic or on glucose-lowering agents, gallbladder symptoms, and nutritional adequacy. Excessive weight-loss pace is a tolerability and safety signal. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- Investigational in the current reference context.
- It is not FDA-approved for any indication until an FDA approval action occurs.
- Availability is limited to clinical-trial or investigational settings.
- Cagrilintide remains development/product-specific rather than a general approved standalone peptide in the guide context. Combination filings or trial results do not simplify into broad approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.